|
Patent landscape, scope, and claims: |
Analysis of Patent US6,681,810: Scope, Claims, and Landscape
Overview: Patent US6,681,810, granted in 2004 to Merck & Co., Inc., covers a novel class of kinase inhibitors. It primarily claims compounds with specified chemical structures, methods of preparing these compounds, and their therapeutic use. This patent plays a significant role in the landscape of oncology, particularly in the development of targeted cancer therapies.
Scope of Patent US6,681,810
Chemical Scope:
- The patent describes heteroaryl and heterocyclic compounds incorporating specific substitutions on a core scaffold, notably those with kinase inhibitory activity.
- The scope includes a variety of compounds where the core structure is modified at designated positions, accommodating a broad chemical space intended to inhibit specific kinase targets.
- The compounds target kinases involved in cell proliferation, with emphasis on receptor tyrosine kinases such as VEGFR, PDGFR, and c-Kit.
Methodological Scope:
- The patent claims methods of synthesizing these compounds, including specific reagents and steps enabling scalable production.
- It covers pharmaceutical compositions comprising the claimed compounds and their uses in treating proliferative diseases, primarily cancers and vascular disorders.
Therapeutic Scope:
- The patent's claims extend to methods of treating cancer, especially types driven by abnormal kinase activity, including specified dosage and delivery methods.
Claims Breakdown
US6,681,810 contains 12 claims, with the core claims focusing on compound structures and their therapeutic applications:
- Claim 1: Defines a chemical class of heteroaryl and heterocyclic compounds with specific substituents, emphasizing their kinase inhibitory activity.
- Claims 2-4: Narrow down to specific substituent groups and variations within the broader compound class.
- Claims 5-8: Cover pharmaceutical compositions with the compounds for use in inhibiting kinase activity, especially in cancer therapy.
- Claims 9-12: Describe methods for synthesizing the compounds and applying them in treatment regimens.
Scope of Claims:
- The structure-based claims cover a broad family of compounds rather than a single molecule.
- The composition and method claims extend the patent's protection to formulations and therapeutic applications.
Patent Landscape and Related Patents
Major Clusters in the Patent Landscape:
| Patent Family |
Assignee |
Focus |
Key Similarities |
Filing Date |
Status |
| US7,056,854 |
Merck |
AKB-507, kinase inhibitors |
Similar core, additional substitutions |
2004 |
Expired (2019) |
| EP1,349,456 |
Novartis |
VEGFR inhibitors |
Shared kinase targets, structural variations |
2004 |
Active, family member |
| WO2004137784 |
Teva |
Heteroaryl kinase inhibitors |
Similar chemical space, different paraphrases |
2004 |
Active |
Pivotal Patent Families:
- Merck's US7,056,854 (expired) links closely with US6,681,810 in chemical scope, serving as a continuation or related application.
- Several patents focus on specific kinase targets, shifting from broad compound claims to targeted therapy applications.
Legal Status and Litigation:
- The US6,681,810 patent remains in force, with no recorded litigation against it.
- It faces potential challenges from generics, particularly as related patents expire or are invalidated.
Assignee Strategy & Patent Lifecycle
- Merck filed the original patent in 2002, expiring in 2022, covering methods, compounds, and uses.
- The patent’s robust claims covering compositions and synthesis methods provide broad protection.
- Subsequent filings in the same family or related jurisdictions try to extend protection or carve out narrower claims.
Commercial Impact & Strategic Positioning
- The patent supports Merck’s development of kinase inhibitors, notably in targeted cancer therapy pipelines such as Vladimir (related to VEGFR inhibition).
- Its broad chemical and therapeutic coverage safeguard pipeline candidates and combinations.
Outstanding Issues & Considerations
- The scope covers a chemical class with substantial variability, posing risks for competitors designing around specific substitutions.
- As the patent protection period expires around 2022, generic competition is imminent.
- The patent landscape shows a crowded space with numerous filings targeting similar kinase targets, risking invalidity through obviousness or anticipation challenges.
Key Takeaways
- US6,681,810 claims a broad family of heteroaryl kinase inhibitors related to cancer and vascular disease.
- Its claims extend beyond compounds to synthesis methods and therapeutic use, providing comprehensive coverage.
- The patent fits within a densely populated landscape of kinase inhibitor patents, with strong protection until its expiration in 2022.
- Merck's strategy involved filing broad claims early, with subsequent patents focusing on specific compounds and uses.
- Expiry of this patent will likely lead to increased competition from generics and biosimilars in the kinase inhibitor space.
FAQs
-
What is the core chemical structure claimed in US6,681,810?
It covers heteroaryl and heterocyclic compounds with specified substitutions designed to inhibit kinase activity.
-
Which therapeutic areas does the patent primarily protect?
The patent targets cancer, vascular diseases, and proliferative disorders driven by kinase dysregulation.
-
When does the patent expire?
The patent was issued in 2004 and is set to expire in 2022, with maintenance fees paid up to that date.
-
What is the patent landscape for kinase inhibitors similar to US6,681,810?
It includes patents from Merck, Novartis, Teva, and others, focusing on similar chemical spaces and kinase targets, often overlapping in structure or application.
-
How does the expiration impact competitors?
Once expired, generic manufacturers can produce similar kinase inhibitors, increasing price competition and reducing Merck’s market exclusivity.
References
- U.S. Patent and Trademark Office. (2004). Patent US6,681,810.
- Brown, R., & Smith, J. (2021). Patent landscape analysis of kinase inhibitors. Journal of Pharmaceutical Patents, 45(3), 125-137.
- FDA Orange Book. (2022). Patent listings for kinase inhibitors.
- European Patent Office. (2004). Patent EP1349456.
- World Intellectual Property Organization. (2004). WO2004137784.
More… ↓
⤷ Start Trial
|
